Physician profile
Rees Adomako
NPI 1063891042
$1,994.62
in general payments reported to CMS, 2019-2025
12 companies · $727 in 2025
The $727 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $239 · 2024: $1,029 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Travel and Lodging: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.73 |
| Travel and Lodging | $752.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $752.89 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $367.57 | 2025 | Wainua |
| Janssen Scientific Affairs, LLC | $168.28 | 2024 | Xarelto |
| Boston Scientific Corporation | $161.73 | 2025 | Avvigo Guidance System, General - Atherectomy |
| Impulse Dynamics (USA) INC. | $159.83 | 2023 | Optimizer |
| Abiomed | $130.62 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.53 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $54.94 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $42.04 | 2024 | Xarelto |
| Pfizer INC. | $38.35 | 2023-2024 | |
| Lantheus Medical Imaging, INC. | $30.16 | 2024 | |
| Edwards Lifesciences Corporation | $29.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rees Adomako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.